Premium
Roles of metformin‐mediated girdin expression in metastasis of epithelial ovarian cancer
Author(s) -
Dang Jianhong,
Gao Jinghai,
Ma Fang,
Luo Yan,
Wang Jing,
Wang Dan,
Li Weiqing,
Sun Hao,
Li Lingling,
Liu Xiaojun,
Hu Dian,
Jin Zhijun
Publication year - 2021
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.11547
Subject(s) - metformin , gene knockdown , ly294002 , downregulation and upregulation , metastasis , cancer research , pi3k/akt/mtor pathway , protein kinase b , medicine , cancer , cell culture , biology , signal transduction , microbiology and biotechnology , insulin , gene , genetics , biochemistry
Antimetastatic effect of Metformin has been documented in epithelial ovarian cancer (EOC). Presently, we investigated the regulatory mechanism of Metformin in EOC metastasis. First, Girdin was significantly enhanced in EOC tumorous tissues and cell lines. Seconded, knockdown of Girdin significantly suppressed EOC cell viability, migration, and invasion, while upregulation of Girdin produced the opposite effects in vitro and facilitated lung metastasis in EOC cell xenograft in vivo. In addition, we confirmed that the inhibitory effect of Metformin on Girdin expression. Mechanistically, the oncogenic effects of Girdin could be reversed by LY294002 (an AKT pathway inhibitor) and Metformin. These results suggested that Metformin attenuated EOC metastasis through Girdin and targeting Girdin may be a promising therapeutic strategy for EOC in the future.